The FDA issued a complete response letter for Corcept Therapeutics’ relacorilant in hypertension secondary to hypercortisolism (Cushing syndrome), asking for additional evidence of efficacy and halting the planned launch. Corcept disclosed the CRL and said it will meet with the agency to chart a path forward in Cushing while redirecting development resources toward a planned July 2026 PDUFA for relacorilant in platinum‑resistant ovarian cancer. The decision removes one near‑term commercial pathway for relacorilant and forces Corcept to rebalance regulatory strategy, safety data packages, and potential labeling discussions for the oncology filing. Market reaction reflected the dual risk: immediate setback in the endocrine indication alongside continued hope for the oncology program.